|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.44 USD | +3.49% |
|
+3.20% | -55.31% |
| Capitalization | 17.1B 16.18B 15B 13.42B 24.18B 1,448B 26.77B 187B 69.01B 595B 64.24B 62.81B 2,564B | P/E ratio 2024 * |
-4.77x | P/E ratio 2025 * | -4.98x |
|---|---|---|---|---|---|
| Enterprise value | 8.98B 8.49B 7.87B 7.04B 12.69B 760B 14.05B 97.97B 36.22B 312B 33.72B 32.97B 1,346B | EV / Sales 2024 * |
2.72x | EV / Sales 2025 * | 4.31x |
| Free-Float |
90.48% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | +3.49% | ||
| 1 week | +3.20% | ||
| Current month | +3.20% | ||
| 1 month | -14.23% | ||
| 3 months | -39.03% | ||
| 6 months | -71.27% | ||
| Current year | -55.31% |
1 week
41.48
46.62
1 month
35.8050.90
Current year
35.80170.47
1 year
35.80170.47
3 years
35.80321.31
5 years
17.68497.49
10 years
11.54497.49
| Director | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 28/02/2011 |
James Mock
DFI | Director of Finance/CFO | 47 | 05/09/2022 |
Stephen Hoge
PSD | President | 48 | 31/01/2015 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 31/05/2018 |
Noubar Afeyan
CHM | Chairman | 61 | 31/01/2012 |
Stéphane Bancel
BRD | Director/Board Member | 51 | 28/02/2011 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +3.49% | +3.20% | -44.86% | -83.25% | 17.1B | ||
| +0.42% | -0.80% | +56.02% | -26.05% | 43B | ||
| +1.35% | +0.89% | -6.01% | -22.98% | 36.78B | ||
| -0.50% | -3.69% | +12.49% | -7.48% | 26.11B | ||
| +3.81% | +3.43% | -18.99% | -18.23% | 17.95B | ||
| -1.26% | -0.22% | +54.04% | +95.88% | 16.5B | ||
| +0.84% | -1.13% | +12.83% | -36.35% | 11.84B | ||
| +2.40% | +2.91% | +25.93% | +71.01% | 10.87B | ||
| +0.14% | -3.64% | -4.42% | -45.41% | 9.81B | ||
| -0.02% | -0.02% | +1.63% | -21.10% | 9.65B | ||
| Average | +0.89% | +0.18% | +8.87% | -9.40% | 19.96B | |
| Weighted average by Cap. | +0.90% | +0.13% | +13.54% | -13.21% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 3.3B 3.13B 2.9B 2.59B 4.67B 280B 5.17B 36.07B 13.33B 115B 12.41B 12.14B 495B | 2.96B 2.81B 2.6B 2.33B 4.19B 251B 4.64B 32.36B 11.96B 103B 11.14B 10.89B 445B |
| Net income | -3.55B -3.36B -3.11B -2.79B -5.02B -301B -5.56B -38.75B -14.33B -124B -13.34B -13.04B -532B | -3.46B -3.27B -3.04B -2.71B -4.89B -293B -5.42B -37.77B -13.96B -120B -13B -12.71B -519B |
| Net Debt | -8.13B -7.69B -7.13B -6.38B -11.49B -688B -12.72B -88.7B -32.79B -283B -30.53B -29.85B -1,218B | -4.33B -4.1B -3.8B -3.4B -6.13B -367B -6.78B -47.29B -17.48B -151B -16.28B -15.91B -650B |
More financial data
* Estimated data
Employees
5,600
Calendar
19/02/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/12/24 | 44.44 $ | +3.49% | 8,742,718 |
| 05/12/24 | 42.94 $ | +3.15% | 8,084,242 |
| 04/12/24 | 41.63 $ | -2.23% | 5,010,891 |
| 03/12/24 | 42.58 $ | -3.80% | 7,192,609 |
| 02/12/24 | 44.26 $ | +2.79% | 6,832,757 |
Delayed Quote Nasdaq, December 06, 2024 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
44.44USD
Average target price
76.41USD
Spread / Average Target
+71.95%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition